innoscripta SE (ETR:1INN)
Germany · Delayed Price · Currency is EUR | Market Cap | 324.50M -72.4% |
| Revenue (ttm) | 122.41M +42.5% |
| Net Income | 51.28M +51.1% |
| EPS | 5.13 +51.1% |
| Shares Out | 10.00M |
| PE Ratio | 6.33 |
| Forward PE | 5.70 |
| Dividend | 4.00 (12.33%) |
| Ex-Dividend Date | Apr 22, 2026 |
| Volume | 150,084 |
| Open | 37.65 |
| Previous Close | 37.25 |
| Day's Range | 31.10 - 38.40 |
| 52-Week Range | 31.10 - 137.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 218.36 (+572.91%) |
| Est. Earnings | Nov 3, 2026 |
About innoscripta SE
innoscripta SE provides software-as-a-service for managing research and development (R&D) tax incentives and project management consulting in Germany, France, and the United Kingdom. It offers solutions for research and development documentation, such as human resources, task management, organization, project management, and time tracking. It serves the additive manufacturing/3D printing; aerospace engineering; automotive; biotechnology; business consulting and technical services; chemical; construction; electrical engineering; energy; environm... [Read more]
Financial Performance
In 2025, innoscripta SE's revenue was 103.41 million, an increase of 59.82% compared to the previous year's 64.71 million. Earnings were 42.61 million, an increase of 69.82%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for 1INN stock is "Strong Buy." The 12-month stock price target is €218.36, which is an increase of 572.91% from the latest price.
News
EQS-Adhoc: innoscripta SE: Searches at innoscripta Group entities in connection with investigations relating to research allowances
EQS-Ad-hoc: innoscripta SE / Key word(s): Other innoscripta SE: Searches at innoscripta Group entities in connection with investigations relating to research allowances 01-Oct-2026 / 13:52 CET/CEST Di...
innoscripta SE Earnings Call Transcript: Q2 2026
Revenue grew 43% year-over-year in H1 2026 to EUR 63 million, with EBIT up 49% to EUR 36.4 million. System migration temporarily impacted Q2, but guidance for EUR 140 million revenue and EUR 80 million EBIT is confirmed. International expansion and improved cash collection support long-term growth.
innoscripta SE Slides: Q2 2026
innoscripta SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 25, 2026.
innoscripta SE Quarterly report: Q2 2026
innoscripta SE has published its Q2 2026 quarterly earnings report on August 25, 2026.
innoscripta SE Quarterly report: Q1 2026
innoscripta SE has published its Q1 2026 quarterly earnings report on May 26, 2026.
innoscripta SE Slides: Q1 2026
innoscripta SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 26, 2026.
innoscripta SE Annual report: Q4 2025
innoscripta SE has published its Q4 2025 annual report on March 20, 2026.
innoscripta SE Annual report: Q4 2025
innoscripta SE has published its Q4 2025 annual report on March 20, 2026.
innoscripta SE Earnings Call Transcript: Q4 2025
Revenue and EBIT surged nearly 60% year-over-year, driven by enterprise client wins and product innovation. Management expects continued high growth and margins, supported by regulatory tailwinds and international expansion, with a focus on shareholder returns.
innoscripta SE Earnings release: Q4 2025
innoscripta SE released its Q4 2025 earnings on February 3, 2026, summarizing the period's financial results.
innoscripta SE Slides: Q4 2025
innoscripta SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
innoscripta SE Quarterly report: Q3 2025
innoscripta SE has published its Q3 2025 quarterly earnings report on November 3, 2025.
innoscripta SE Slides: Q3 2025
innoscripta SE has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 3, 2025.